Evidence associating endocrinopathies such as diabetes, thyroid and growth hormone disorders with cardiomyopathies (CMs) and heart failure (HF) has been longestablished. Initially, endocrine disorders were considered an independent risk factor for the development of HF. However, increasing diagnosis of endocrine disorders in patients with CM suggest the involvement of hormones in the pathogenesis of CMs. Moreover, the success of hormonal replacement therapies in a sub-population of patients diagnosed with dilated cardiomyopathy (DCM) provides additional evidence for the role of hormones in the pathophysiology of CMs. In addition, identifying endocrine disorders able to cause CM is important since early initiation of hormonal replacement therapy or surgery can normalize hormonal levels and potentially reverse cardiac dysfunction. However, specific guidelines for the diagnosis and management of endocrine CM are lacking. This has been partly occasioned by a paucity of clinical trials specific to endocrine CM attributed to a disproportionate focus of CM literature on the long-established morphofunctional forms of CM, particularly dilated, hypertrophic and restrictive CMs. Thus, this paper reviews current published data on endocrine CM. In particular, the paper discusses specific endocrine disorders capable of causing CM including their pathophysiology diagnosis and treatment.